Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Humacyte (HUMA) Retained Earnings (2024 - 2025)

Humacyte has reported Retained Earnings over the past 2 years, most recently at -$726.8 million for Q4 2025.

  • Quarterly results put Retained Earnings at -$726.8 million for Q4 2025, down 5.95% from a year ago — trailing twelve months through Dec 2025 was -$726.8 million (down 5.95% YoY), and the annual figure for FY2025 was -$726.8 million, down 5.95%.
  • Retained Earnings for Q4 2025 was -$726.8 million at Humacyte, down from -$702.0 million in the prior quarter.
  • Over the last five years, Retained Earnings for HUMA hit a ceiling of -$569.2 million in Q1 2024 and a floor of -$726.8 million in Q4 2025.